These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19609945)

  • 1. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model.
    Lamour V; Le Mercier M; Lefranc F; Hagedorn M; Javerzat S; Bikfalvi A; Kiss R; Castronovo V; Bellahcène A
    Int J Cancer; 2010 Apr; 126(8):1797-1805. PubMed ID: 19609945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells.
    Wu XL; Lin KJ; Bai AP; Wang WX; Meng XK; Su XL; Hou MX; Dong PD; Zhang JJ; Wang ZY; Shi L
    World J Gastroenterol; 2014 Aug; 20(30):10440-8. PubMed ID: 25132760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity.
    Henry A; Nokin MJ; Leroi N; Lallemand F; Lambert J; Goffart N; Roncarati P; Bianchi E; Peixoto P; Blomme A; Turtoi A; Peulen O; Habraken Y; Scholtes F; Martinive P; Delvenne P; Rogister B; Castronovo V; Bellahcène A
    Oncotarget; 2016 Sep; 7(39):63708-63721. PubMed ID: 27563812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo.
    Lamour V; Henry A; Kroonen J; Nokin MJ; von Marschall Z; Fisher LW; Chau TL; Chariot A; Sanson M; Delattre JY; Turtoi A; Peulen O; Rogister B; Castronovo V; Bellahcène A
    Int J Cancer; 2015 Sep; 137(5):1047-57. PubMed ID: 25620078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.
    Hahnel A; Wichmann H; Kappler M; Kotzsch M; Vordermark D; Taubert H; Bache M
    Radiat Oncol; 2010 Sep; 5():82. PubMed ID: 20849637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer.
    Du XL; Jiang T; Sheng XG; Gao R; Li QS
    Gynecol Oncol; 2009 Dec; 115(3):371-6. PubMed ID: 19783287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment.
    Szulzewsky F; Schwendinger N; Güneykaya D; Cimino PJ; Hambardzumyan D; Synowitz M; Holland EC; Kettenmann H
    Neuro Oncol; 2018 Feb; 20(3):355-366. PubMed ID: 29016864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal.
    Selkirk SM; Morrow J; Barone TA; Hoffer A; Lock J; DeChant A; Mangla S; Plunkett RJ; Miller RH
    J Neurooncol; 2008 Feb; 86(3):285-96. PubMed ID: 17928956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells.
    Wang ZM; Cui YH; Li W; Chen SY; Liu TS
    Oncol Rep; 2011 Apr; 25(4):997-1003. PubMed ID: 21286666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of osteopontin in the regulation of human bladder cancer proliferation and migration in T24 cells.
    Xu ST; Guo C; Ding X; Fan WJ; Zhang FH; Xu WL; Ma YC
    Mol Med Rep; 2015 May; 11(5):3701-7. PubMed ID: 25591934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells.
    Yan W; Qian C; Zhao P; Zhang J; Shi L; Qian J; Liu N; Fu Z; Kang C; Pu P; You Y
    Neuro Oncol; 2010 Aug; 12(8):765-75. PubMed ID: 20511184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Knocking down osteopontin expression by specific siRNA reduces the in vitro invasiveness of human hepatocellular carcinoma cells].
    Zhu XQ; Ye QH; Lei KF; Chen J; Qin LX
    Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):404-7. PubMed ID: 17152482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.
    Teixeira LN; de Castro Raucci LM; Alonso GC; Coletta RD; Rosa AL; de Oliveira PT
    Tumour Biol; 2016 Sep; 37(9):12371-12385. PubMed ID: 27312487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.
    Yang L; Zhao W; Zuo WS; Wei L; Song XR; Wang XW; Zheng G; Zheng MZ
    Chin Med J (Engl); 2012 Jan; 125(2):293-9. PubMed ID: 22340562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
    Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
    Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines.
    Wohlleben G; Scherzad A; Güttler A; Vordermark D; Kuger S; Flentje M; Polat B
    Radiat Oncol; 2015 Aug; 10():167. PubMed ID: 26259597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
    Beausoleil MS; Schulze EB; Goodale D; Postenka CO; Allan AL
    BMC Cancer; 2011 Jan; 11():25. PubMed ID: 21247495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small interfering RNA targeting osteopontin as gastric cancer therapeutics.
    Gong M; Lu Z; Fang G; Bi J; Xue X
    Cancer Lett; 2008 Dec; 272(1):148-59. PubMed ID: 18694621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells.
    Wang Y; Yan W; Lu X; Qian C; Zhang J; Li P; Shi L; Zhao P; Fu Z; Pu P; Kang C; Jiang T; Liu N; You Y
    Eur J Cell Biol; 2011 Aug; 90(8):642-8. PubMed ID: 21616556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer.
    Cheng HC; Liu YP; Shan YS; Huang CY; Lin FC; Lin LC; Lee L; Tsai CH; Hsiao M; Lu PJ
    Carcinogenesis; 2013 Nov; 34(11):2452-9. PubMed ID: 23774402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.